New Delhi, UK-based pharmaceutical major AstraZeneca has started withdrawing its COVID-19 vaccine, which was provided in India as Covishield in partnership with the Serum Institute of India, over concerns about blood clotting. And a few days after acknowledging the rare side effects of low platelet counts.
The company said in a statement that the recall was initiated due to the abundance of updated vaccine available since the pandemic began.
AstraZeneca had partnered with Oxford University to develop the COVID-19 vaccine, which was sold as Covishield in India and Vaxjavria in Europe.
It added, "As many types of COVID-19 vaccines have been developed, there is a glut of updated vaccines available. This has led to a decline in demand for Vaxzervaria, which is no longer being manufactured or supplied "
The company added, “We will now work with regulators and our partners to close this chapter and move forward on a clear path to making a significant contribution to the COVID-19 pandemic.,
Earlier, according to global media reports, AstraZeneca had admitted that its COVID-19 vaccine has the potential to cause a rare side effect in very rare cases, called thrombosis with thrombocytopenia syndrome (TTS).
Without mentioning side effects, the company said, "We are incredibly proud of the role Vaxjavria played in ending the global pandemic. According to independent estimates, more than 6.5 million lives were saved in the first year of use alone and “More than three billion doses were administered.” “Supplied globally.”
It added, “Our efforts have been recognized by governments around the world and are widely considered a critical component of ending the global pandemic.,
In India, more than 220 crore doses of COVID-19 vaccines have been administered, the majority of which were Covishield.
The company said in a statement that the recall was initiated due to the abundance of updated vaccine available since the pandemic began.
AstraZeneca had partnered with Oxford University to develop the COVID-19 vaccine, which was sold as Covishield in India and Vaxjavria in Europe.
It added, "As many types of COVID-19 vaccines have been developed, there is a glut of updated vaccines available. This has led to a decline in demand for Vaxzervaria, which is no longer being manufactured or supplied "
The company added, “We will now work with regulators and our partners to close this chapter and move forward on a clear path to making a significant contribution to the COVID-19 pandemic.,
Earlier, according to global media reports, AstraZeneca had admitted that its COVID-19 vaccine has the potential to cause a rare side effect in very rare cases, called thrombosis with thrombocytopenia syndrome (TTS).
Without mentioning side effects, the company said, "We are incredibly proud of the role Vaxjavria played in ending the global pandemic. According to independent estimates, more than 6.5 million lives were saved in the first year of use alone and “More than three billion doses were administered.” “Supplied globally.”
It added, “Our efforts have been recognized by governments around the world and are widely considered a critical component of ending the global pandemic.,
In India, more than 220 crore doses of COVID-19 vaccines have been administered, the majority of which were Covishield.
